Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Depression, Unipolar
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study examines the efficacy of bright light therapy as a treatment for adolescents diagnosed with unipolar non-seasonal depression who exhibit an evening chronotype.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Bright light therapy — Exposure to blue-enriched white light for 15-30 minutes a day for 8 weeks
  • Device: Dim red light — Exposure to dim red light for 15-30 minutes a day for 8 weeks.

Primary Outcomes

  • Change of depressive symptoms (Soon after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2028-06-30
Eligibility
Age: 12 Years – 19 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Joey WY Chan
+852 39197647
joeywychan@cuhk.edu.hk
Joey WY Chan, FHKAM(Psych)
+862 39197647
joeywychan@cuhk.edu.hk
The Chinese University of Hong Kong
Xingle Gao
+852 92916602
xinglegao@link.cuhk.edu.hk
The Chinese University of Hong Kong
Interventions
  • Device: Bright light therapy — Exposure to blue-enriched white light for 15-30 minutes a day for 8 weeks
  • Device: Dim red light — Exposure to dim red light for 15-30 minutes a day for 8 weeks.
Study Locations (1 sites)
The Chinese University of Hong Kong, Hong Kong, Hong Kong 999077 Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. Chinese, aged 12-19 years old; 2. Written informed assent/consent of participation into the study is given by the participant and his/her parent or guardian (for those aged under 18), respectively; 3. Having a DSM-5 diagnosis of unipolar non-seasonal depression as confirmed by the Chinese version of the Kiddie-Schedule for Affective Disorders and Schizophrenia (K-SADS) psychiatric interview, DSM-5 Seasonal specifier, AND having a score on Children's Depression Rating Scale (CDRS-R) at least 40; 4. Being classified as evening chronotype according to the score on the reduced Horne-Östberg Morning-Eveningness Questionnaire (rMEQ), i.e. \<12. Exclusion Criteria: 1. A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, organic mental disorders, or intellectual disabilities; 2. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt) as assessed by K-SADS; 3. Having been enrolled in any other clinical trial investigational products within one month at the entry of the study; 4. Initiation of or change in antidepressant medication within past 4 weeks; 5. Having been or is currently receiving any structured psychotherapy; 6. With hearing or speech deficit; 7. Night shift worker; 8. Trans-meridian flight across at least two time zones in the past 3 months and during the study; 9. Presence of an eye disease, e.g., retinal blindness, severe cataract, glaucoma.
Conditions Compassion
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Objectives: This 3-year study aims to develop, refine, and evaluate a brief compassion-based intervention specifically designed for family caregivers of lung cancer patients. In the first year, the primary focus will be on developing the intervention content and assessing its feasibility and acceptability. In the second and third years, the goal will be to assess the intervention's effects on depression and anxiety. Method: In the first year, the intervention will be developed in three stages. Initially, the intervention will be created based on compassion-focused theory and evidence-based exercises, incorporating feedback from family caregivers in previous studies and insights from professionals to ensure its relevance to lung cancer caregivers. Next, a pilot study will test the intervention's feasibility and acceptability with 30 family caregivers, using mixed methods to gather session-by-session feedback and assess recruitment, retention, and adherence. Following the pilot, the intervention will be revised based on participant and researcher feedback, preparing it for further study. In the second and third years, a randomized controlled trial (RCT) will be conducted with 84 participants randomly assigned to either the 4-session Brief Compassion-Based Intervention (BCI) or a single-session Telephone-Based Support and Education (TSE) control group. Outcomes, including depression, anxiety, caregiver stress, mindfulness, self-compassion, and self-efficacy, will be measured at baseline, immediately post-intervention, and at 3- and 6-month follow-ups. For data analysis, long-term follow-up quantitative data will be analyzed using the Generalized Estimating Equation (GEE) to examine group differences. Moderation and mediation analyses will be conducted to explore potential moderators and mechanisms of the intervention. Qualitative data from interviews will be analyzed using content analysis. Expected Results: This study is expected to provide a comprehensive understanding of the feasibility, acceptability, and effectiveness of compassion-based interventions for lung cancer caregivers, contributing to their application in clinical care practice.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Brief Compassion-Based Intervention (BCI) — The intervention program is based on Compassion-Focused Therapy (CFT) and incorporates evidence-based compassion exercises.Drawing on insights from the literature, the program includes:Session 1: Introduction to caregiving challenges and emotional systems. Includes a soothing breathing exercise and group discussion on caregiving stress. Session 2: Cultivating self-compassion. Includes reflecting on emotions, guided meditation, and a compassionate body scan practice. Session 3: Transforming self-criticism into self-compassion. Caregivers explore self-critical thoughts, practice reframing, and engage in compassionate dialogue. Session 4: Building resilience and connections. Focuses on gratitude, setting boundaries, and loving-kindness meditation, ending with daily intention setting.
  • Behavioral: Telephone-Based Support and Education (TSE) — The session will address their questions and concerns, provide psychological support for managing difficult emotions (e.g., anxiety, fear, sadness, and guilt), and emphasize the importance of self-care, encouraging them to take time for themselves and seek support when needed.

Primary Outcomes

  • Hospital Anxiety and Depression Scale (HADS) Questionnaire (From baseline through study completion, up to 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2028-02-28
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Medical University
Collaborators: National Science and Technology Council
Contact Information
Study Contact:
Chia-Chen Hsieh, PhD
+886 2 2736 1661
chiachenh@tmu.edu.tw
Chia-Chen Taipei Medical University
+886-2-2736-1661
chiachenh@tmu.edu.tw
Taipei Medical University
Interventions
  • Behavioral: Brief Compassion-Based Intervention (BCI) — The intervention program is based on Compassion-Focused Therapy (CFT) and incorporates evidence-based compassion exercises.Drawing on insights from the literature, the program includes:Session 1: Introduction to caregiving challenges and emotional systems. Includes a soothing breathing exercise and group discussion on caregiving stress. Session 2: Cultivating self-compassion. Includes reflecting on emotions, guided meditation, and a compassionate body scan practice. Session 3: Transforming self-criticism into self-compassion. Caregivers explore self-critical thoughts, practice reframing, and engage in compassionate dialogue. Session 4: Building resilience and connections. Focuses on gratitude, setting boundaries, and loving-kindness meditation, ending with daily intention setting.
  • Behavioral: Telephone-Based Support and Education (TSE) — The session will address their questions and concerns, provide psychological support for managing difficult emotions (e.g., anxiety, fear, sadness, and guilt), and emphasize the importance of self-care, encouraging them to take time for themselves and seek support when needed.
Study Locations (1 sites)
Taipei Medical University, Taipei, Taiwan 11031 Taiwan
Eligibility Criteria
Inclusion Criteria: * Primary family caregiver of a person with newly diagnosed lung cancer (within one year of diagnosis) * Aged 20 years or older * Access to a computer or smartphone with internet connection at home Exclusion Criteria: * Currently receiving psychological therapy * Diagnosed with a severe mental illness and taking medication for it (e.g.,psychosis, bipolar disorder) * Previous experience with mindfulness or self-compassion training
Conditions Major Depressive Disorder
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this proposal is to determine whether heightened negative affective responsivity (NA-R) to daily stressors is related to blunted nitric oxide (NO)-mediated endothelium-dependent dilation (EDD) in working age adults and the extent to which this association is impacted by major depressive disorder (MDD).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: NG-nitro-L-arginine methyl ester (L-NAME) — Acute local perfusion of L-NAME (15 mM) directly to the microvasculature will be used to inhibit NO synthase.

Primary Outcomes

  • Nitric oxide (NO)-mediated endothelium-dependent dilation (EDD) (immediately before and after the 14-day testing cycle)
  • Negative affective responsivity (NA-R) to daily stressors (immediately after the 14-day testing cycle)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-06
Completion: 2031-12-01
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Delaware
Collaborators: National Institute of General Medical Sciences (NIGMS)
Contact Information
Study Contact:
Jody Greaney, PhD
302-831-2193
jgreaney@udel.edu
Jody Greaney, PhD
302-831-2193
jgreaney@udel.edu
University of Delaware
Interventions
  • Other: NG-nitro-L-arginine methyl ester (L-NAME) — Acute local perfusion of L-NAME (15 mM) directly to the microvasculature will be used to inhibit NO synthase.
Study Locations (1 sites)
University of Delaware, Newark, Delaware 19713 United States
Eligibility Criteria
Inclusion Criteria: * Males and females aged 18-55 yrs * Non-depressed health adults (HA) will have no evidence of current or lifetime history of major psychiatric illness, assessed by the MINI and self-report and confirmed by a Licensed Clinical Psychologist * Adults with major depressive disorder (MDD) must meet the DSM-5 criteria for MDD and be currently symptomatic, assessed by the MINI and confirmed by a Licensed Clinical Psychologist; participants with co-morbid anxiety, stress, and trauma-related disorders will be included * Absence of unstable or chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease, as determined by medical history, physical examination, blood chemistries, and 12-lead resting electrocardiogram; however, to ensure a more generalizable sample, adults with elevated systolic BP (\<130mmHg), direct low-density lipoprotein (\<160mg/dl), and glucose (HbA1c \<5.7%) will be included * Participants must have a level of understanding of the English language sufficient to provide informed consent and to agree to all tests and procedures, as well as the capacity and willingness to attend all study related visits and to comply with the study protocol Exclusion Criteria: Subjects will be excluded at the discretion of the PI/collaborating clinicians or for any of the following reasons: * \<18 or \>55 yrs * Lifetime or current co-morbid neuropsychiatric disease (bipolar disorder, psychotic disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, alcohol or substance use disorders) * Serious and imminent active suicidal/homicidal ideation with intent, plans, or behaviors, determined by the Licensed Clinical Psychologist or other clinical study team staff * Diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease, as determined by medical history, physical examination (resting systolic BP ≥130mmHg, body mass index ≥35 kg/m2), clinically significant abnormal blood chemistries (direct low-density lipoprotein ≥160mg/dl, HbA1c≥5.7%), and clinically significant abnormal 12-lead resting ECG * Current or recent use (within last 8 wks) of medications that alter cardiovascular function or psychoactive or psychopharmacological drugs \[including (but not limited to) antidepressants, antipsychotics, benzodiazepines, mood stabilizers, sedatives/hypnotics, dopaminergic agents, stimulants, buspirone, and triptans\] * Tobacco use (including electronic cigarettes) * Females who are pregnant, breastfeeding, or planning to become pregnant; female subjects of child-bearing age must have a negative urine pregnancy test on the day of all experimental visits * Current or past use of hormone replacement therapy * Allergy to study drugs or pharmacological agents
Conditions Depression, Anxiety Disorders
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Identifying predictors and understanding mechanisms of change will inform referral to psychotherapy, triage and right-siting by helping clinicians to understand how their patients are likely to benefit from clinical interventions. This study will be the first of its kind conducted in an Asian hospital setting to identify the predictors of response to individual, group and internet-delivered CBT for the treatment of depressed and anxious patients in the Institute of Mental Health (IMH), Singapore. With increasing challenges with hospital workload, there is an increasing emphasis on group and online interventions. Understanding of the factors that may predict outcome from these therapies can improve right-siting by identifying who will get better without therapy or who may not benefit from a given form of therapy and guide personalisation of care. An important biological predictor of outcome is likely to be genetic risk as it has been demonstrated that patients with greater melancholia and a family history may not be sufficiently treated with brief courses of therapy. Identifying psychological factors underlying psychological distress and determining the extent to which these factors are addressed by these interventions will help to improve and individualise existing psychotherapy and motivate new psychotherapeutic interventions.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Individual Psychotherapy — The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
  • Behavioral: Internet-delivered Cognitive Behavioural Therapy (iCBT) — The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: "1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs)", are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- "increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues".
  • Behavioral: Group Cognitive Behavioural Therapy (group CBT) — The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.

Primary Outcomes

  • Change in Patient Health Questionnaire-9 (PHQ-9) score (Immediately before each therapy session for 8 sessions (i.e. 8 weeks for iCBT and group therapy, or approximately 16 weeks for individual therapy), and at follow-up every 3 months up to 2 years.)
  • Change in Generalized Anxiety Disorder-7 (GAD-7) questionnaire score (Immediately before each therapy session for 8 sessions (i.e. 8 weeks for iCBT and group therapy, or approximately 16 weeks for individual therapy), and at follow-up every 3 months up to 2 years.)
  • Change in Outcome Rating Scale (ORS) score (Immediately before each therapy session for 8 sessions (i.e. 8 weeks for iCBT and group therapy, or approximately 16 weeks for individual therapy).)
  • Change in Work and Social Adjustment Scale (WSAS) score (At baseline, at post-intervention (immediately after the final therapy session i.e. at 8 weeks for iCBT and group therapy, or at approximately 16 weeks for individual therapy), and at follow-up every 3 months up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-10-04
Completion: 2026-09-30
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Mental Health, Singapore
Principal Investigators:
  • Geoffrey CY Tan (PRINCIPAL_INVESTIGATOR) - Institute of Mental Health, Singapore
Contact Information
Study Contact:
Geoffrey CY Tan
+65 63891923
geoffrey_tan@imh.com.sg
Geoffrey CY Tan
+65 63891923
geoffrey_tan@imh.com.sg
Institute of Mental Health, Singapore
Interventions
  • Behavioral: Individual Psychotherapy — The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
  • Behavioral: Internet-delivered Cognitive Behavioural Therapy (iCBT) — The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: "1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs)", are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- "increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues".
  • Behavioral: Group Cognitive Behavioural Therapy (group CBT) — The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
Study Locations (1 sites)
Institute of Mental Health, Singapore, Singapore, Singapore 539747 Singapore
Eligibility Criteria
Inclusion Criteria: 1. For patients: 1. 18-99 years old; 2. have current or past symptoms of anxiety and/or depression; 3. able to communicate and read in English; 4. able to provide informed consent. 5. Waitlist arm: \- Referred for psychotherapy but given a waiting time of 8 weeks or more to the first visit or not assigned to therapy at IMH. 6. Treatment as usual: \- Not assigned to any psychotherapeutic interventions. 7. iCBT: - Referred for iCBT; \- Identified as a 'P2' patient/appropriate for iCBT by triage. 8. Group therapy: \- Referred for group therapy; \- Identified as a 'P2' patient/appropriate for group therapy by triage. 9. Individual psychotherapy: * Referred for individual therapy; * Patient and therapist committed to frequent therapy (ideally fortnightly). 2. For therapists: 1. Therapists who will see OR have been assigned to clients in the waitlist arm, iCBT, group therapy (e.g. PsychUp), and individual psychotherapy group. Exclusion Criteria: 1\. For patients: 1. current active suicidal intention or plan; 2. cognitively-impaired/are unable to consent/lack capacity to consent.
Conditions Major Depressive Disorder (MDD), Cogniti...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Individuals with depression often describe difficulties with memory, attention, concentration, and overall cognitive functioning, which can persist even after mood episodes get better, and can affect treatment and health outcomes. The primary objective of this pilot clinical trial is to evaluate the feasibility and acceptability of a manualized, 8-week, Compensatory Cognitive Training (CCT) intervention for Veterans who received treatment for MDD in the past year and have persistent cognitive functioning deficits. The investigators will compare Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD) to a robust comparator, Goal-focused Supportive Contact (GSC), to evaluate differences in outcome measures. The investigators hypothesize that Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD) will be feasible and acceptable to participants in a pilot trial of ME-CCT-MDD vs. Goal-focused supportive contact (GSC) for Veterans with recent MDD treatment and persistent cognitive symptoms. This study will also evaluate the preliminary magnitude and direction of symptom change on measures of objective cognitive functioning, psychiatric symptomatology, psychosocial functioning, and quality of life. The investigators hypothesize that CCT will improve objective cognitive functioning, psychiatric outcomes, psychosocial functioning, and quality of life in Veterans with recent MDD-related cognitive functioning deficits. Participants who agree to participate in the study will: 1. Take part in an assessment of their cognition, symptoms, and functioning, which will take approximately 2 hours. The assessment will include an interview about their medical, psychiatric, and cognitive history. It will also include questionnaires about their symptoms and daily functioning as well as neuropsychological tests, which are paper-pencil tests that evaluate aspects of cognition such as memory, attention, and problem-solving skills. 2. Be randomly assigned (like the flip of a coin) to receive Goal-Focused Supportive Contact or Compensatory Cognitive Training. Both treatments will involve weekly groups with a mental health provider for approximately 2 hours per week for 8 weeks. Goal-Focused Treatment includes setting and achieving short-term and long-term goals for improving cognition and functioning. Compensatory Cognitive Training includes training in strategies to improve cognition and manage stress. 3. Complete a follow-up assessment of cognition, symptoms, and functioning 8 weeks after they begin treatment, as well as a brief interview about their experience in the group. These assessment sessions will take approximately 2 hours.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD) — 8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.
  • Behavioral: Goal-focused Supportive Contact — 8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.

Primary Outcomes

  • Recruitment Rate (From enrollment to the end of treatment at 8 weeks)
  • Study Retention (From enrollment to the second assessment (within 2 weeks post-treatment))
  • Rate of Intervention Completion (From enrollment to the end of treatment at 8 weeks)
  • Feasibility of Testing Procedures (From enrollment to the second assessment (within 2 weeks post-treatment))
  • Feasibility of data collection methods (From enrollment to the second assessment (within 2 weeks post-treatment))
  • Acceptability, by participant report (From enrollment to the second assessment (within 2 weeks post-treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Portland VA Medical Center
Collaborators: Oregon Health and Science University
Principal Investigators:
  • Maya O'Neil, PhD (PRINCIPAL_INVESTIGATOR) - Portland VA Medical Center
  • Joren Adams (PRINCIPAL_INVESTIGATOR) - Portland VA Medical Center
Contact Information
Study Contact:
Joren Adams
503-220-8262
joren.adams@va.gov
Joren Adams
503-220-8262
joren.adams@va.gov
Portland VA Medical Center
Interventions
  • Behavioral: Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD) — 8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.
  • Behavioral: Goal-focused Supportive Contact — 8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.
Study Locations (1 sites)
Portland VA Medical Center, Portland, Oregon 97239 United States
Eligibility Criteria
Inclusion Criteria: 1. Veterans 18 years of age or older 2. Self-reported concerns about cognitive functioning deficits or clinical concerns about cognitive functioning deficits documented in EHR 3. meets DSM-5 criteria for MDD and receiving treatment for this diagnosis at the Portland VA within the past year 4. moderate or greater depressive symptoms as assessed by a PHQ-9 score ≥ 10 5. current cognitive functioning deficits as determined by performance on at least two measures in one cognitive domain (i.e., memory, attention/processing speed, language, executive functioning) falling ≥1 SD below their age-appropriate norms in the absence of memory impairment. Exclusion Criteria: 1. impaired capacity to understand study risks and benefits 2. history of TBI as defined by American College of Rehabilitation Medicine and VA/DoD criteria 3. meets DSM-5 criteria for a substance use disorder other than nicotine use disorder in the past 6 months 4. meets DSM-5 criteria for dementia, psychotic disorder, or "with psychotic features" specifier 5. active suicidal intent with significant clinical risk 6. auditory or visual impairments that would prevent ability to participate in cognitive rehabilitation group or assessments. Eligibility will be established by electronic medical record review conducted by study staff and will be confirmed by the Veteran during the initial phone call.
Conditions Psychosis, Bipolar and Related Disorders...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Researchers aim to test a brief culturally-responsive young adult orientation program for community mental health services. They will conduct a 24-month randomized trial with 80 young adults from racial and ethnic minority groups in a community-based mental health clinic.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Just Do You — Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
  • Behavioral: Component A — Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
  • Behavioral: Component B — Content addresses identity-based motivations for on-going engagement with services and hope for the future.
  • Behavioral: Component C — Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.

Primary Outcomes

  • Participant acceptability questionnaire (Immediately after the intervention)
  • Qualitative interviews (Immediately after the intervention)
  • Intervention adherence (Baseline through study completion, an average of 2 years; repeated measure to assess change through study completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-18
Completion: 2027-03
Eligibility
Age: 18 Years – 34 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: New York University
Contact Information
Study Contact:
Kiara L Moore, PhD
212-998-5900
kiara.moore@nyu.edu
Christina Mango
718-282-3425
CMango@jbfcs.org
The Jewish Board
Interventions
  • Behavioral: Just Do You — Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
  • Behavioral: Component A — Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
  • Behavioral: Component B — Content addresses identity-based motivations for on-going engagement with services and hope for the future.
  • Behavioral: Component C — Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
Study Locations (1 sites)
The Jewish Board, The Bronx, New York 10457 United States
Eligibility Criteria
Inclusion Criteria: * Aged 18-34 * From groups other than non-Hispanic White * Enrolled in services at the partnering clinic site Exclusion Criteria: * Cognitive impairments (i.e., young adult cannot understand consent process) * Unable to comprehend and speak English
Conditions Esketamine, ECT, Depression, Adolescent
Phase EARLY_PHASE1
Enrollment 220
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT. The sample size was calculated based on the response rate of patients with depression undergoing electroconvulsive therapy(ECT).According to the results of the pilot study,the efficacy rate of subjects receiving adjunctive esketamine was approximately 78%,while the efficacy rate of those receiving only propofol was 63%.The expected superiority difference in remission rates between the two groups was 15%(one-sided)for the power calculation.Assuming a significance level of α=0.05 and a test power of β=0.2,with a 1:1 ratio of sample sizes between the two groups,the total sample size was calculated to be 198 using the PASS software(PASS 2023).Considering a dropout rate of 10%,a total of 220 subjects were required,with 110 subjects in each group. 1. experimental group The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy. 2. In the control group The patients were given normal saline consistent with esketamine injection volume, 1.5mg/kg of propofol and 1mg / kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy. Efficacy evaluation 1. Main efficacy indicators Response rate of depressive symptoms after MECT treatment Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized. Participants will: Be randomly assigned to the esketamine group or the control group, and receive standard MECT treatment. Have seizure parameters, seizure duration, vital signs, and complications recorded. Complete psychiatric scale assessments, including HAMD-24, BSS, PANSS, WMS-RC and MoCA. Be assessed at the following time points: HAMD-24 and BSS after each treatment; PANSS after each treatment course;WMS-RC and MoCA before MECT and after one treatment course. All subjects did not discontinue antidepressants before modified electroconvulsive therapy(MECT),and they were fasting for 8 hours and no fluids for 2 hours.Three minutes before MECT,continuous qCON monitoring(Apollo-9000A,Chongqing Xideer Medical Equipment Co.,Ltd.,China)was initiated,while monitoring blood pressure,heart rate,and peripheral capillary oxygen saturation.Preoxygenation was administered for 3 minutes.The qCON monitor uses three electrodes on the forehead to collect raw electroencephalogram(EEG)signals.The qCON monitoring includes the qCON index,qNOX index,burst suppression(BS),and signal quality…

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Esketamine injection group (0.25 mg/kg) — The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.
  • Other: Saline injection group (Consistent with esketamine injection volume) — The main anesthesiologist standing on the right side of the patient injects saline (Consistent with esketamine injection volume) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.

Primary Outcomes

  • Treatment response rate (immediately after the end of each MECT procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-11-25
Completion: 2026-12-20
Eligibility
Age: 13 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Min Su
Principal Investigators:
  • Su Min (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital of Chongqing Medical University
Contact Information
Study Contact:
Xiaoge Han, Master
023-89011061
3164233689@qq.com
Su Min, MD
+86-23-89011068
ms89011068@163.com
The First Affiliated Hospital of Chongqing Medical University
Su Min
0086-023-89011876
ms89011068@163.com
The First Affiliated Hospital of Chongqing Medical University
Interventions
  • Drug: Esketamine injection group (0.25 mg/kg) — The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.
  • Other: Saline injection group (Consistent with esketamine injection volume) — The main anesthesiologist standing on the right side of the patient injects saline (Consistent with esketamine injection volume) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.
Study Locations (2 sites)
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Eligibility Criteria
Inclusion Criteria: * Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT); * Aged 13 to 17 years,regardless of gender; * Educational attainment of primary school or higher; * Normal hearing and vision,including color perception; * Voluntary participation in the study with signed informed consent; * American Society of Anesthesiologists(ASA)physical status classification I-II. Exclusion Criteria: * Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions; * Inability to complete the assessment scales; * History of substance abuse; * Received electroconvulsive therapy(ECT)within 6 months prior to the study; * Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes; * Severe allergy or contraindication to propofol or succinylcholine; * Comorbid with other psychiatric disorders.

Cocooned Moms Study

NCT06968650
Recruiting
Conditions Stress, Depression, Pregnancy, Blood Pre...
Phase NA
Enrollment 384
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digital and Coordinated Maternial Care — The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.

Primary Outcomes

  • Change in depression, anxiety, and stress as measured by Depression Anxiety Stress Scales- Short Form (DASS-21) (Up to 7 months)
  • Pittsburgh Sleep Quality Index (PSQI) (Up to 7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2026-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: InovCares Connected Comprehensive Healthcare Corporation
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR)
Contact Information
Study Contact:
Judite Blanc, PhD
3052437452
cocoonedstudy@miami.edu
Mohamed Kamara
(614) 749-4256
mkamara@inovcares.com
Judite Blanc, PhD
305-243-7542
juditeblanc@miami.edu
University Of Miami
Interventions
  • Behavioral: Digital and Coordinated Maternial Care — The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.
Study Locations (2 sites)
University Of Miami, Miami, Florida 33136 United States
Dr.Traci's House, Tampa, Florida 33604 United States
Eligibility Criteria
Inclusion Criteria: \- Black Women ages 18 + with confirmed pregnancy of at least eight or up to 28 weeks, with no known fetal or genetic abnormalities (with the exception of abnormal amniotic fluid volume; Women who have the developmental or legal capacity to consent; Able to speak English Exclusion Criteria: * Exclusion criteria 1. Psychosis diagnosis 2. Does not speak or understand English 3. Participants who are not pregnant 4. Non-Black 5. Significant vision impairment.
Conditions Depression, OCD, Anxiety Depression
Phase Not Applicable
Enrollment 12000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Device: Patients treated with NeuroStar TMS — non-invasive brain stimulation device
  • Drug: Patients treated with Esketamine — nasal spray for treating depression

Primary Outcomes

  • change in clinical outcome scores from baseline to post treatment (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-15
Completion: 2035-12
Eligibility
Age: 5 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 12000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neuronetics
Principal Investigators:
  • Eleanor Cole, PhD (STUDY_DIRECTOR) - Neuronetics
Contact Information
Study Contact:
Neha Goyal
7635281599
neha.goyal@neurostar.com
Eleanor Cole, PhD
415-724-7960
Eleanor.cole@neurostar.com
Eleanor Cole
Neuronetics
Interventions
  • Device: Patients treated with NeuroStar TMS — non-invasive brain stimulation device
  • Drug: Patients treated with Esketamine — nasal spray for treating depression
Study Locations (1 sites)
Neuronetics, Malvern, Pennsylvania 19355 United States
Eligibility Criteria
Inclusion Criteria: * Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date in 2011 or later. Exclusion Criteria: • Incomplete information on treatment parameters
Conditions Alcohol Use Disorder
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This pilot randomized clinical trial will evaluate the feasibility, acceptability, and preliminary effectiveness of immersive Virtual Reality (VR) nature intervention among adults with at least moderate depression symptoms enrolled in an intensive outpatient Program (IOP) for Alcohol Use Disorder (AUD). The study hypotheses: * VR-based nature immersion will be feasible, acceptable, and positively evaluated by participants * Participants receiving the VR intervention will report greater reductions in symptoms of depression, anxiety, and stress compared to those receiving standard care alone

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Virtual Reality (VR) -nature treatment — Participants assigned to the VR intervention will engage in 5 to 30-minute (gradual increase in duration as tolerated to prevent motion sickness) -3 times per week, immersive VR nature sessions over 4 weeks, using the Apple Vision Pro and Explore POV app, alongside standardintensive outpatient program (IOP) care or other treatments they are receiving (e.g., additional counseling, psychiatry, etc.).
  • Behavioral: Survey completion — All participants will complete surveys at various time-points (baseline - 9 weeks).

Primary Outcomes

  • Enrollment rates (Recruitment period (approximately 18 months))
  • Attendance at scheduled VR sessions (4 weeks of VR)
  • Adherence to VR (4 weeks of VR)
  • Percentage of participants that complete the entire study duration -VR (4 weeks of VR)
  • Number of participants with documentation of informed consent completion (Recruitment period (Approximately 18 months))
  • The Virtual Reality Neuroscience Questionnaire (VRNQ) (4 weeks of VR)
  • Changes in depression measured by Patient Health Questionnaire-9 (PHQ-9) (Baseline, 4 weeks, 8 weeks)
  • Changes in anxiety measured by the Generalized Anxiety Disorder-7 (GAD-7) (Baseline, 4 weeks, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-16
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Principal Investigators:
  • Hala Darwish, PhD (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Zee Petrie
734-647-3357
petrieli@med.umich.edu
Hala Darwish, PhD
734-647-4929
darwishh@med.umich.edu
Zee Petrie
734-647-3357
petrieli@med.umich.edu
University of Michigan
Interventions
  • Device: Virtual Reality (VR) -nature treatment — Participants assigned to the VR intervention will engage in 5 to 30-minute (gradual increase in duration as tolerated to prevent motion sickness) -3 times per week, immersive VR nature sessions over 4 weeks, using the Apple Vision Pro and Explore POV app, alongside standardintensive outpatient program (IOP) care or other treatments they are receiving (e.g., additional counseling, psychiatry, etc.).
  • Behavioral: Survey completion — All participants will complete surveys at various time-points (baseline - 9 weeks).
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Individuals with a documented AUD diagnosis * Individuals enrolled in an Intensive Outpatient Program (IOP) (First week enrollment or planned enrollment in Michigan Medicine's Addiction Treatment Services (UMATS) IOP) * Individuals with a Patient Health Questionnaire (PHQ-9) score (≥10, moderate or greater depression symptoms) Exclusion Criteria: * Severe motion sickness or sensitivity to VR-induced nausea or dizziness (anticipated \<10%), medical contraindications to VR use (e.g., seizure disorders, vestibular disorders, agoraphobia, claustrophobia, psychosis). * Significant cognitive impairments that prevent provision of informed consent * Suicidal ideation or plan after consultation with treating clinician * Participants who require vision correction with glasses, unless vision correction is mild (±1), or the participant does not have prescription contact lenses.
Conditions Functional Dyspepsia, Probiotics, Depres...
Phase PHASE4
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Objective: This study aims to evaluate the effectiveness of Clostridium butyricum in improving anxiety and depression in patients diagnosed with functional dyspepsia according to the Rome IV criteria. Methods: This trial plans to enroll 180 patients (90 per group). The study will employ a double-blind design. For patients diagnosed with FD according to the Rome IV criteria, in addition to conventional treatment (treated with Mosapride Citrate Tablets (Guangdong Anno Guocai) for Postmeal Discomfort Syndrome (PDS) and Esomeprazole Enteric Coated Tablets (Shijiazhuang Longze Pharmaceutical Guocai) for Upper Abdominal Pain Syndrome (EPS)), the experimental group was treated with Clostridium butyricum, while the control group received a placebo with the same appearance and odor. The treatment intervention will last for 4 weeks. The main indicator of this experiment is the improvement of the Hospital Anxiety and Depression Scale (HADS score) after 4 weeks of treatment. The secondary indicators are the improvement rate of the overall treatment effectiveness evaluation questionnaire (OTE questionnaire), the improvement of the global overall symptom score (GOS score), the improvement of the simplified Nipin scale (SF-NDI), and the improvement of the Pittsburgh Sleep Index (PSQI) after 4 weeks of treatment. Upon completion of the trial, the patients' conditions will be re-evaluated, and treatment plans will be adjusted accordingly.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Clostridium butyricum — Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily. Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily.
  • Drug: placebo — Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency). Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).

Primary Outcomes

  • Hospital Anxiety and Depression Scale (HADS) (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-03-26
Completion: 2027-05-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital of Digestive Diseases
Contact Information
Study Contact:
Yongquan Shi Shi
029-84771515
shiyquan@fmmu.edu.cn
Interventions
  • Drug: Clostridium butyricum — Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily. Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily.
  • Drug: placebo — Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency). Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).
Study Locations (1 sites)
Air Force Medical University, Xi’an, Shanxi China
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with functional dyspepsia (FD) according to the Rome IV criteria. * Aged 18 to 80 years, regardless of gender. * Hospital Anxiety and Depression Scale (HADS) score between 8 and 14. Exclusion Criteria: * Use of probiotics or antibiotics within one month prior to the trial. * Use of psychoactive medications (including hypnotics, sedatives, anxiolytics, or antidepressants) within one month prior to the trial. * Use of hormones, immunosuppressants, or cytotoxic agents within one month prior to the trial. * Participation in any other clinical trial within one month prior to the study. * Positive test for Helicobacter pylori (Hp) infection. * Long-term use of traditional Chinese herbal medicine. * Pregnancy or lactation. * History of drug abuse. * Comorbidities such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), functional constipation (FC), or other significant conditions that may interfere with the trial-including severe hepatic, renal, respiratory, or autoimmune disorders; bleeding diatheses; psychiatric diseases; endocrine disorders; etc. * History of major surgery or diagnosis of diabetes mellitus. * Refusal to provide written informed consent.
Conditions Depressive Symptoms, Mild Traumatic Brai...
Phase NA
Enrollment 198
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the efficacy, safety, and tolerability of two dorsolateral prefrontal cortex (DLPFC) repetitive transcranial magnetic stimulation (rTMS) protocols to alleviate symptoms of depression in United States (U.S.) military service members and veterans with a history of concussion/mild traumatic brain injury (TBI).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Repetitive Transcranial Magnetic Stimulation (rTMS) — Active rTMS
  • Device: Sham rTMS — Sham comparator to active rTMS

Primary Outcomes

  • Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (Baseline to post-intervention, within 10 working days of the final rTMS session)
  • Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Scores in a Subgroup (Baseline to post-intervention, within 10 working days of the final rTMS session)
  • Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores from Baseline to 6-month follow-up (Baseline to 6 months)
  • Comparison of Treatment Response or Remission in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (Baseline to post-intervention, within 10 working days of the final rTMS session)
  • Comparison of Duration of Remission of Depressive Symptoms in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (Follow-up Period, from 1-6 months after the final rTMS session)
  • Comparison of Frequency of Adverse Events (Baseline to post-intervention, within 10 working days of the final rTMS session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-16
Completion: 2026-12-31
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 198 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: Uniformed Services University of the Health Sciences, Congressionally Directed Medical Research Programs
Principal Investigators:
  • David L Brody, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uniformed Services University of the Health Sciences
Contact Information
Study Contact:
Elizabeth N Diaz Nelson, MPH
832-671-9532
elizabeth.nelson.ctr@usuhs.edu
Rachel Dieterich
Rachel.Dieterich@va.gov
VA Palo Alto Health Care System
Maheen M Adamson, PhD
VA Palo Alto Health Care System
Interventions
  • Device: Repetitive Transcranial Magnetic Stimulation (rTMS) — Active rTMS
  • Device: Sham rTMS — Sham comparator to active rTMS
Study Locations (3 sites)
VA Palo Alto Health Care System, Palo Alto, California 94304 United States
William Beaumont Army Medical Center, Fort Bliss, Texas 79918 United States
Alexander T. Augusta Military Medical Center, Fort Belvoir, Virginia 22060 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-55 at the time of consent. Older individuals will not be enrolled in this initial trial for reasons of safety and expected reduced efficacy. * Current or former US military service member eligible for care at a Military Treatment Facility (MTF) or Veterans Administration Medical Center (VAMC.) * Able to provide written, informed consent in English . * Self-reported or medically diagnosed history of concussion (synonymous with "mild TBI.") \>6 months, but \<26 years prior to consent, defined based on the DoD/VA definition: 1. Positive Loss of Consciousness of \<30 minutes as confirmed by the TBI Screener and/or medical records and/or; 2. Positive Alteration of Consciousness of \<24 hours as confirmed by the TBI Screener and/or medical records and/or; 3. Positive Post-traumatic Amnesia of 0 to 1 day as confirmed by the TBI Screener and/or medical records. * Note: Neuroimaging data or documentation from medical records is not required. * Baseline MADRS \>13 at the time of screening indicating at least mild-moderate depressive symptoms. * Maintained a steady psychotropic medication regimen for six weeks and a steady behavioral therapy regimen for twelve weeks prior to enrollment in the study. * Female participants with child-bearing potential must agree to use an effective method of birth control during the course of the study. * Under the care of a primary care and/or behavioral health provider. Exclusion Criteria: * Elevated risk of seizures at the time of rTMS including any of the following: 1. History of unprovoked seizures. 2. History of seizure within 24 hours of sustaining a concussion(s) or other head injury regardless of whether it was determined to have been related to concussion. 3. Family history of two or more unprovoked seizures in a first degree relative (parent, sibling, or child). 4. History of Moderate, Severe, or Penetrating TBI based on TBI Screener and/or medical records. 5. Intracranial lesion (such as intracranial tumor or intraparenchymal hemorrhage) that, in the opinion of the investigators, would increase seizure risk. 6. Currently taking medication or other substances (such as tricyclic antidepressants or neuroleptics) that, in the opinion of the investigator, lowers the seizure threshold. * Contraindications to awake 3T MRI without contrast at the time of the Baseline MRI according to site radiology department criteria. * Severe claustrophobia interfering with medication/sedation-free 3T closed-bore MRI. * Intracranial lesion that would produce an artifact that would compromise the integrity of rsfMRI data. * History of severe or recent uncontrolled heart disease. * Presence of a cardiac pacemaker or intracardiac lines. * Any implant, prosthesis or other permanent alteration of the body (such as implanted neurostimulators and medication pumps) that, in the opinion of the investigator, would be unsafe with MRI or TMS or that would produce an artifact that would compromise the integrity of data. * Presence of rapidly progressive illnesses such as late-stage cancer, neurodegenerative conditions, major organ failure, etc. * History of Bipolar Disorder or Schizophrenia Spectrum Disorders. * Current evidence of substance-induced mood disorder, active psychosis, or depression secondary to general medical illness other than TBI. * Severe or uncontrolled substance use. * Concomitant or lifetime history of receiving open-label TMS, due to issues preserving blinding. * Concomitant or recent history (within 12 weeks prior to enrollment) of receiving other neurostimulatory treatment, including but not limited to transcranial direct current (tDCS), transcranial alternating current (tACS), alpha stim, or electroconvulsive therapy. * Suicide attempt within six months prior to enrollment. * Right upper extremity amputation or other condition precluding left motor threshold calibration. * Unable to complete timeline of study (e.g., planned hospitalization partway through the study period.) * Prisoner, or other legally restricted freedom of movement and participation. * Any other considerations that, in the opinion of the investigators, may adversely affect participant safety, participation, or the scientific validity of the data being collected (e.g., erratic or unreliable responses, inconsistent communication, inability to remain on a steady neurotropic medication and/or behavioral therapy regimen over the course of the Randomization phase of the study.)